Welcome to new Emergence client, Dalriada Therapeutics Inc.

January 25, 2017

We are happy to extend a warm “EmerGence welcome” to our newest client, Dalriada Therapeutics Inc., from Mississauga, Ontario. Welcome to Canada’s bioscience incubation program!

dalriadaDalriada Therapeutics Inc. is a start-up focusing on the development of novel small molecules for a range of therapeutic and diagnostic applications.

With broad expertise in drug discovery and chemosensor technologies, the company’s efforts are currently centred on the preclinical development of a novel class (DT1) of small molecule inhibitors in cancers of the blood and brain as well as proliferative skin pathologies.

Dalriada is engaged in the development of small molecule-based diagnostic technologies for Alzheimer’s disease and infections.

In addition to these R&D activities, Dalriada offers services in medicinal chemistry and custom synthesis.

Dalriada’s founders:



Dr. Patrick Gunning, Chief Scientific Officer, Dalriada Therapeutics Inc.

Dr. Patrick T GunningChief Scientific Officer – Patrick is a world leader in the development of small molecule inhibitors targeting the STAT3 and STAT5 oncogenes. He currently holds the rank of Full Professor and is a Canada Research Chair in Medicinal Chemistry at the University of Toronto. Patrick is the inaugural Director of Centre of Medicinal Chemistry at the University of Toronto Mississauga.

Patrick has over 100 peer-reviewed publications, presented over 120 invited lectures, and published over 140 abstracts at conferences worldwide. He is the principal inventor on 10 patent applications, with several licensed to industrial partners. Patrick is the recipient of 18 National and international awards in 9 years and his work attracted $15 million in research grants and ~$8 M in philanthropic donations.


Dr. Diana Kraskouskaya, Chief Executive Officer, Dalriada Therapeutics, Inc.

Dr. Diana Kraskouskaya, Chief Executive Officer – With a BSc degree in molecular Biology and a PhD degree in medicinal chemistry, Diana has a broad expertise in drug discovery and 6 years of experience in the management of multi-faceted research programs.

Diana has presented at multiple research conferences, is an author of 8 research publications, and is a recipient of 19 personal awards and scholarships. For the past two years, Diana has directed the research operations of the Gunning Group, managing a team of 20 full time (post)graduate and ~ 15 rotating undergraduate staff and researchers, managed >$1.2 M yearly operating budget and directed a $7 M research infrastructure development project.